Peptide-mediated liposomal doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Chang, De Kuan ^a   Li, Pi Chun ^a   Lu, Ruei Min ^a   Jane, Wann Neng ^b   Wu, Han Chung ^a  

^a INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^b INSTITUTE OF PLANT AND MICROBIAL BIOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, SCID; POLYETHYLENE GLYCOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893608874     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083239     Document Type: Article

References (56)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Peto R, Chen ZM, Boreham J (1999) Tobacco - the growing epidemic. Nat Med 5: 15-17. (Pubitemid 29050987)
3. Novello S, Le Chevalier T (2003) Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park) 17: 357-364.
4. Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, et al. (2010) Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 68: 89-93.
5. Baish JW, Gazit Y, Berk DA, Nozue M, Baxter LT, et al. (1996) Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res 51: 327-346. (Pubitemid 26162001)
6. Gazit Y, Berk DA, Leunig M, Baxter LT, Jain RK (1995) Scale-invariant behavior and vascular network formation in normal and tumor tissue. Phys Rev Lett 75: 2428-2431.
7. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
8. Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813. (Pubitemid 39331152)
9. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, et al. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21: 418-429.
10. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, et al. (1998) Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 58: 1195-1201. (Pubitemid 28183208)
11. Chang DK, Lin CT, Wu CH, Wu HC (2009) A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One 4: e4171.
12. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2: 750-763.
13. Chinn P, Braslawsky G, White C, Hanna N (2003) Antibody therapy of non-Hodgkin's B-cell lymphoma. Cancer Immunol Immunother 52: 257-280. (Pubitemid 36581906)
14. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, et al. (2004) Targeted therapies for cancer 2004. Am J Clin Pathol 122: 598-609. (Pubitemid 39281258)
15. Haran G, Cohen R, Bar LK, Barenholz Y (1993) Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151: 201-215. (Pubitemid 23283973)
16. Wu HC, Chang DK (2010) Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. J Oncol 2010: 723798.
17. Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303: 1818-1822. (Pubitemid 38374867)
18. Muggia F, Hamilton A (2001) Phase III data on Caelyx in ovarian cancer. Eur J Cancer 37 Suppl 9: S15-18.
19. Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, et al. (2007) Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 18: 716-721. (Pubitemid 46523276)
20. Frenkel V, Etherington A, Greene M, Quijano J, Xie J, et al. (2006) Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure. Acad Radiol 13: 469-479.
21. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, et al. (2005) Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A 102: 12962-12967. (Pubitemid 41279472)
22. Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC (2007) Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 67: 10958-10965.
23. Lee TY, Wu HC, Tseng YL, Lin CT (2004) A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res 64: 8002-8008.
24. Lu RM, Chang YL, Chen MS, Wu HC (2011) Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32: 3265-3274.
25. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, et al. (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8: 1172-1181. (Pubitemid 35177372)
26. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, et al. (2006) Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 66: 10073-10082. (Pubitemid 44672061)
27. Chang DK, Chiu CY, Kuo SY, Lin WC, Lo A, et al. (2009) Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem 284: 12905-12916.
28. Lo A, Lin CT, Wu HC (2008) Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 7: 579-589. (Pubitemid 351482141)
29. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, et al. (1997) Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36: 66-75. (Pubitemid 27024679)
30. Cai W, Chen X (2008) Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc 3: 89-96.
31. Laginha KM, Verwoert S, Charrois GJ, Allen TM (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 11: 6944-6949. (Pubitemid 41428752)
32. Mayer LD, Dougherty G, Harasym TO, Bally MB (1997) The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280: 1406-1414. (Pubitemid 27166739)
33. Lee RJ, Wang S, Turk MJ, Low PS (1998) The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci Rep 18: 69-78. (Pubitemid 28438379)
34. Voigt W (2005) Sulforhodamine B assay and chemosensitivity. Methods Mol Med 110: 39-48.
35. Harding C, Heuser J, Stahl P (1983) Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 97: 329-339.
36. Miller AD (2003) The problem with cationic liposome/micelle-based non-viral vector systems for gene therapy. Curr Med Chem 10: 1195-1211.
37. Miller AD (2004) Nonviral liposomes. Methods Mol Med 90: 107-137.
38. Zuhorn IS, Hoekstra D (2002) On the mechanism of cationic amphiphile-mediated transfection. To fuse or not to fuse: is that the question? J Membr Biol 189: 167-179. (Pubitemid 36930154)
39. Thomas P, Lee AK, Wong JG, Almers W (1994) A triggered mechanism retrieves membrane in seconds after Ca(2+)-stimulated exocytosis in single pituitary cells. J Cell Biol 124: 667-675.
40. Artalejo CR, Henley JR, McNiven MA, Palfrey HC (1995) Rapid endocytosis coupled to exocytosis in adrenal chromaffin cells involves Ca2+, GTP, and dynamin but not clathrin. Proc Natl Acad Sci U S A 92: 8328-8332.
41. Farge E, Ojcius DM, Subtil A, Dautry-Varsat A (1999) Enhancement of endocytosis due to aminophospholipid transport across the plasma membrane of living cells. Am J Physiol 276: C725-733. (Pubitemid 29157390)
42. Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11: 123-134.
43. Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91 Suppl 2: S18-23. (Pubitemid 39331428)
44. Maule M, Scelo G, Pastore G, Brennan P, Hemminki K, et al. (2007) Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. J Natl Cancer Inst 99: 790-800. (Pubitemid 47073525)
45. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905. (Pubitemid 28446849)
46. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, et al. (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7: 243-254. (Pubitemid 32183025)
47. Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, et al. (2001) A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 34: 427-432. (Pubitemid 33041478)
48. Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14: 1310-1316. (Pubitemid 351413909)
49. Mukherjee S, Ghosh RN, Maxfield FR (1997) Endocytosis. Physiol Rev 77: 759-803. (Pubitemid 27328740)
50. Mellman I, Fuchs R, Helenius A (1986) Acidification of the endocytic and exocytic pathways. Annu Rev Biochem 55: 663-700. (Pubitemid 16070784)
51. Petros RA, DeSimone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9: 615-627.
52. Frei E 3rd, Elias A, Wheeler C, Richardson P, Hryniuk W (1998) The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res 4: 2027-2037. (Pubitemid 28415644)
53. Frei E 3rd, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585-594.
54. Falciani C, Accardo A, Brunetti J, Tesauro D, Lelli B, et al. (2011) Target-selective drug delivery through liposomes labeled with oligobranched neurotensin peptides. ChemMedChem 6: 678-685.
55. Kok MB, Hak S, Mulder WJ, van der Schaft DW, Strijkers GJ, et al. (2009) Cellular compartmentalization of internalized paramagnetic liposomes strongly influences both T1 and T2 relaxivity. Magn Reson Med 61: 1022-1032.
56. Tseng YL, Liu JJ, Hong RL (2002) Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol 62: 864-872.